Introduction
Memory B cells (MBCs) play a central role in immune memory thanks to their ability to rapidly differentiate into cells that secrete high affinity antibodies (Ab) in response to a secondary antigenic challenge. Several MBC subsets have been described, including a poorly characterized population of MBCs that express Fc receptor-like 4 (FCRL4) [1] [2] [3] . FCRL4 belongs to the family of Fc receptor-like proteins that are expressed mainly by the B-cell lineage [4] . Members a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 of this family contain immunoreceptor tyrosine-based activation (ITAM) and/or inhibition motifs (ITIM) that could modulate their immunoregulatory potential. In healthy individuals, FCRL4 + B cells account for about 10% of tonsil B cells, whereas they are not detected in peripheral blood and bone marrow and are rare in the marginal zone of B cell follicles in spleen and lymph nodes [5] [6] [7] [8] . Conversely, they are present in the peripheral blood of patients with chronic activation of the immune system, such as HIV-infected viremic individuals [9] and patients with hepatitis C virus-associated mixed cryoglobulinemia [10] . FCRL4 + B cells are also detected in the synovial fluid of patients with rheumatoid arthritis where they produce cartilage-and bone-destroying cytokines and could be the main target of anti-CD20 monoclonal antibody (mAb) therapy [11, 12] . Moreover, FCRL4 polymorphisms have been associated with the susceptibility and severity of ankylosing spondylitis [13] . FCRL4 + MBCs are hyporesponsive to stimuli that activate classical MBCs and are considered to be exhausted MBCs [7, 9] . Exhaustion of B-cell activation by HIV can be reversed by knocking down FCRL4 expression [14] . Also the HIV envelope protein gp120 binds to α4β7 integrin on B cells and induces TGFβ secretion and FCRL4 expression that are associated with B cell abortive proliferative response [15] . FCRL4 binds efficiently to IgA and could be important for immune complex-dependent B-cell regulation [16] . Compared with FCRL4 -MBCs, transcriptomic and proteomic analyses have shown that FCRL4 + B cells are characterized by overexpression of cell-surface molecules (particularly, CD20, CD11c and the chemokine receptors CCR1, CCR5 and CCR6), src-family kinases (FGR, HCK, LYN), transcription factors (SOX5, RUNX2, DLL1), and activation-induced cytidine deaminase (AICDA) [6, 7, 9, 10, 12, 17] . Given the link of FCRL4 + B cells with chronic diseases, it would be important to develop a culture model to better understand their generation and function. We previously reported that during differentiation of human MBCs into preplasmablasts (prePBs), we obtained a population of activated CD20 high CD38 -B lymphocytes that strongly express FCRL4 [18] . Here, we show that in vitro generated FCRL4 + B cells share multiple characteristics with in vivo FCRL4 + B cells. Differently from prePBs and PBs (FCRL4 -cells) generated using the same culture conditions, FCRL4 + cells have a low proliferation rate and are not prone to differentiate into plasmacells (PCs).
Materials and methods Reagents
Human recombinant IL-2 was purchased from R&D Systems (Minneapolis, MBCs were sorted using a multi-color fluorescence FACS Aria device, as previously described [19] . When indicated, cells were FACS-sorted using a PE-conjugated anti-FCRL4 mAb. The purity of FACS-sorted cell populations was !95%, as assayed by cytometry.
Cell cultures
Step1. B-cell activation. All cultures were performed in Iscove's modified Dulbecco medium (IMDM, Invitrogen) and 10% fetal calf serum (FCS) (Invitrogen). Purified MBCs were cultured in the presence of 20 U/ml IL-2, 50 ng/ml IL-10 and 10 ng/ml IL-15 in 6-well culture plates (1.5 x 10 5 /ml cells in 5 ml/well). Ten μg/ml of phosphorothioate CpG ODN 2006 (ODN) (Sigma) [20] , 50 ng/ml histidine-tagged recombinant human soluble CD40 ligand (sCD40L) and 5 μg/ml anti-poly-histidine mAb (R&D Systems) were added at the culture start.
Step 2. PB generation. At day (D) 4 of culture, cells were harvested, washed and 2.5 x 10 5 / ml cells were seeded in IMDM/10% FCS with 20 U/ml IL-2, 50 ng/ml IL-6, 50 ng/ml IL-10 and 10 ng/ml IL-15.
Step 3. PC generation. At D7 of culture, cells were harvested and 5 x 10 5 / ml cells were seeded in IMDM/10% FCS with 50 ng/ml IL-6, 10 ng/ml IL-15 and 500 U/ml IFN-α for 3 days.
Immunophenotypic analysis
Cells were stained with combinations of mAbs conjugated to different fluorochromes. For intracellular staining of cytoplasmic (cy) IgM, -IgA, and-IgG, surface staining was performed prior to cell fixation and permeabilization using the Cytofix/Cytoperm kit (BD Biosciences), according to the manufacturer's recommendations. Flow cytometry analysis was performed with a FACSAria cytometer using FACSDiva 6.1 (Becton Dickinson, San Jose, CA) and with a Cyan ADP cytometer driven by the Summit software (Beckman Coulter). For data analysis, Cell Quest (Becton Dickinson) and Summit, Kaluza (Beckman Coulter) softwares were used. The fluorescence intensity of the cell populations was quantified using the stain index (SI) formula: [mean fluorescence intensity (MFI) obtained from a given mAb minus MFI obtained with the control mAb]/[2 times the standard deviation of the MFI obtained with the same control mAb] [21] . 
Analysis of Ig secretion

CFSE labeling
Cell division was assessed by carboxyfluorescein succinimidyl ester (CFSE) labeling, as previously described [22] . Briefly, purified MBCs were washed and re-suspended at a concentration of 10 6 cells/ml in PBS/0.1% BSA with 10 μM CFSE (Molecular Probes, Eugene, OR), incubated at 37˚C for 10 minutes and extensively washed before culture. At D4 of culture, cells were washed and labeled with anti-PB-CD20, anti-PerCP-Cy5.5-CD38 and anti-FCRL4-PE mAbs for flow cytometry analysis. Cell divisions were quantified using the ModFit LT software (Verity Software House, Topsham, ME Gene expression data were analyzed with our bioinformatics platform GenomicScape (www. genomicscape.com) [23] . Clustering was performed and visualized with Cluster and TreeView [24] . Differentially expressed genes between cell populations were identified with the significance analysis of microarray (SAM) statistical method (paired Wilcoxon statistics, fold change ! 2, 200 permutations, false decovery rate 0.01) [25, 26] . Gene annotation and networks were generated with the Reactome Functional Interaction Cytoscape plugin (http:// www.cytoscape.org/).
Statistical analysis
Results were compared using the non-parametric Mann-Whitney test, unpaired or paired Student's t-tests and the SPSS software. P-values .05 were considered significant. 
Results
Generation of FCRL4 + B cells In vitro
Characterization of FCRL4 + B cells
To specifically characterize FCRL4 + B cells, whole genome transcriptome analysis was performed using purified in vitro generated FCRL4 + and FCRL4 -B cells at D4 (three independent experiments). Paired SAM supervised analysis (ratio !2, false discovery rate 0.01) identified 527 genes that were significantly upregulated and 457 genes that were downregulated in FCRL4 + compared with FCRL4 -cells (S1 Table) . In vitro-derived FCRL4 + cells displayed a gene expression profile close to that of ex vivo FCRL4 + B cells [7, 17] , with high expression of genes encoding various surface markers, including CD20, CD11c and CD40, several members of the chemokine receptor family (CCR1, CCR5, and CCR6) and the SOX5 transcription factor (Fig  2A) . Flow cytometry analysis confirmed overexpression of CD11c, CD20, CD40 and CCR6 (CD196) and of other surface proteins, including CD1c, CD19 and CD24, in FCRL4 + cells ( Fig   3A , Table 1 [6, 7, 9, 10, 12, 17, 28, 29] and could be a feature of in vitro generated FCRL4 + cells.
Moreover, pathway enrichment analysis using Reactome (false discovery rate <0.001) showed that genes coding for proteins involved in B cell activation, B cell receptor signaling, antigen processing and presentation were significantly enriched in FCRL4 + cells (S2 Table) .
Conversely, genes involved in cell cycle and cell proliferation were significantly downregulated in FCRL4 + B cells compared with FCRL4 -cells (Fig 2B and S2 Table) .
In vitro generated FCRL4 + cells expressed the same inhibitory receptor genes than the FCRL4 + tissue-like memory B cells described by Moir and collaborators in blood of HIV-positive viremic individuals [9, 14] . Particularly, the genes encoding CD22 (Siglec-2), CD32B (FcγRIIB), CD72 and CD85j (LILRB1) (Fig 2C) (Fig 4A) . At this time, cells had not proliferated and activation by ODN and/or CD40L was required for induction of FCRL4 expression (Fig 4B) . Cytokines alone induced FCRL4 expression only in few cells, and addition of the cytokine cocktail did not increase the percentage of FCRL4 + cells at D1 compared with CD40L and/or ODN alone (Fig 4B) . The percentage of FCRL4 + cells decreased by two-fold at D3 and by four-fold at D4, although the total number of cells increased significantly between D3 and D4 due to proliferation (Fig 4C) . Indeed, the absolute number of FCRL4 + cells did not increase from D1 to D4 (Fig 4D) . and 5B). These results were consistent with the downregulation of cell cycle genes and upregulation of inhibitory receptor genes in FCRL4 + B cells (Fig 2B and 2C 
sorted FCRL4
+ cells retained FCRL4 expression at D4 (Fig 6A) . Conversely, most (82%) purified FCRL4 -cells remained FCRL4 negative. As shown in Fig 5 with conditions that favor PC differentiation for another 3 days (step 3) (Fig 7) and had not differentiated into PBs and PCs, as indicated by the absence of CD38 and maintenance of CD20 expression (Fig 7) . (Fig 8C and 8D) . Indeed, due to their reduced proliferation and differentiation potential, at D10, the number of PCs derived from D4-purified FCRL4 + B cells was four times lower compared with that from sorted FCRL4 -B cells (Fig 8E) . 
Discussion
The presence of atypical MBCs FCRL4 + in the blood has been described in different pathologies associated with chronic activation of the immune system [9] . In healthy individuals, the localization of FCRL4 + B cells is essentially limited to mucosa-associated lymphoid tissues (tonsils, Peyer's patches) [5] [6] [7] [8] . Here, using our in vitro PC differentiation model [19] we gen- + and FCRL4 -cells were sorted by flow cytometry and cultured separately. At D7 and D10 of culture, expression of CD20, CD38, CD138 and FCRL4 was analyzed in non-sorted cells (total cells) and sorted FCRL4 + from blood have the potential to express FCRL4. This suggests that in vitro-generated FCRL4 + cells do not constitute a specific MBC class. According to these results, FCRL4 expression results from sustained MBC activation and can be transient (Fig 9) .
This could explain why in healthy individuals, FCRL4 + MBCs are located in tonsils (i.e., a site particularly exposed to pathogens and with continuous ongoing immune responses [7, 25, 31] and its ability to induce B cell exhaustion in HIV-infected individuals with high viremia and in patients with hepatitis C virusassociated mixed cryoglobulinemia [9, 10, 14, 15] . Clearly, the difference in BCR class expression could also contribute to differential signalling pathways since both the IgG and IgA BCR-classes were previously shown to boost proliferation and/or plasma cell commitment [32] [33] [34] [35] [36] . FCRL4 role in cell cycle inhibition is also supported by the concomitant overexpression of src-tyrosine kinases family members (HCK, FGR, LYN) and of the tyrosine phosphatase SHP1. Ehrhardt et al. have shown that FCRL4 activation results in tyrosine phosphorylation of ITIM domains by src-family kinases. This leads to SHP1 and SHP2 phosphatase recruitment and inhibition of BCR signaling [25, 30] . Our transcriptome analysis showed that ten inhibitory receptors with ITIM domains are significantly overexpressed in FCRL4 + B cells compared with FCRL4 -cells, suggesting that they could also be involved in this process. However, among these receptors, FCRL4 is the top upregulated gene in activated B cells at D4. The major role of FCRL4 in activated B cell inhibition is in agreement with the finding that HIV-associated B cell exhaustion can be overcome by using siRNAs against nine cell inhibitory receptors and that FCRL4 silencing has the strongest effect [14] . Moreover, analysis of FCRL family gene expression at the different steps of MBC differentiation to PCs [23] shows that FCRL4 is specifically expressed in activated B cells (S3 Fig). FCRL4 is a receptor for human IgA [16] , it is possible that endogenous IgA secreted in the culture, mainly by FCRL4 -cells, activate this receptor inducing an inhibition of the proliferation of FCRL4 + cells (Fig 9) . During immune response activation in vivo, this could also constitute a mechanism to control FCRL4 + cell expansion through IgA produced by Characterization of human FCRL4-positive B cells showing that cell proliferation is mandatory for B cell differentiation into PCs [37] . Of note, in our culture system, FCRL4 expression was associated with a reduced number of cell divisions. As the two culture systems are quite similar, these data suggest that the poorly cycling B cells unable to differentiate into PCs described by Tangye et al. are in vitro generated FCRL4 + B cells.
Abnormal expression of FCRL4 and of other members of the FCRL family in B cells has been observed in many infectious and autoimmune diseases and could contribute to disorders leading to impaired immune or inflammatory response. Currently, the mechanisms involved in pathological FCRL4 + B cell generation are actively studied, but they remain elusive. Analysis of their normal counterpart could help understanding these mechanisms. As FCRL4 + cells are difficult to isolate ex vivo, our in vitro model could be of major interest for studying the biology of normal and pathological FCRL4+ cells. Gene expression was evaluated using Affymetrix microarrays as previously described (19, 20, 28 
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